Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
List view / Grid view
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
Researchers report that reduced TDP-43 expression disrupts axonal transport of messenger RNAs to cause neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Researchers have revealed the molecular mechanism behind a rare mutation has been associated with numerous neurodegenerative diseases...